Advanced Pancreatic Cancer clinical trials

Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)

This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.

Study of DM002 for advanced solid tumors

This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.

Study of ETX-19477 for advanced solid tumors

This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).

Registry for outcomes in KRAS G12R pancreatic cancer on MEK therapy

This study keeps a registry (a secure database) to track how people with advanced pancreatic cancer and a KRAS G12R mutation do after treatment with a MEK inhibitor–based combination. It helps doctors understand which outcomes matter most for this specific genetic type of cancer.

CyberKnife radiation for certain pancreatic cancer patients after chemotherapy

This trial studies how safe CyberKnife is when used to treat some borderline resectable or locally advanced pancreatic cancers after chemotherapy. It may help patients by targeting the tumor with precise radiation, while researchers closely watch for side effects.

Using a glowing dye to help see pancreatic cancer during surgery

This trial tests whether a special dye (SGM-101) can help surgeons see remaining cancer cells during surgery for pancreatic cancer that has been treated before surgery. It may lead to more complete removal of the tumor.

Study of IM-1021 for advanced B-cell lymphoma or solid tumors

This trial tests a new drug, IM-1021, for people with advanced B-cell lymphomas or certain solid tumors that have not responded to or have come back after standard treatments. The drug targets a protein called ROR1 on cancer cells to try to stop the cancer from growing.

Pancreatic cancer biopsy-guided chemo before surgery

This trial uses a special gene test on fluid taken from an endoscopic ultrasound (EUS) biopsy to help choose chemotherapy before surgery for pancreas cancer. It aims to see if this approach improves outcomes by matching treatment to the tumor’s RNA pattern.

Test drug that targets CD73, alone or with immunotherapy

This early-stage study tests mavrostobart (an anti-CD73 antibody) to see what dose is safe and whether it can help shrink tumors. It’s studied by itself and also with a PD-1 immune therapy or chemotherapy, depending on your cancer type and prior treatments.

QL1706 plus chemo for advanced pancreatic cancer

This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy, with or without another drug (bevacizumab), for people with advanced pancreatic cancer that has not been treated before. It aims to see if this combination can help shrink tumors or slow the disease.

Combination therapy for locally advanced or recurrent pancreatic cancer

This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.

Cell therapy for advanced pancreatic cancer

This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.

Losartan for pancreatic cancer with high blood pressure

This trial tests if adding losartan (a blood pressure medicine) to standard chemotherapy helps people with advanced pancreatic cancer. It is for patients who also have high blood pressure.

Endoscopic ultrasound ablation plus immunotherapy for pancreatic cancer

This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.

Test to detect risky changes in pancreatic cysts

This study looks for molecular (lab) signals that may show advanced or higher-risk changes in certain pancreatic cysts. It may help doctors better sort which cysts are more concerning and may need closer attention.

Sigvotatug vedotin for advanced solid tumors that spread

This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.

Scoring system study for advanced pancreatic cancer

This study looks at a scoring system to predict how well people with advanced pancreatic cancer might do after their first chemotherapy. If you have been diagnosed with this type of cancer and are about to start or have just finished your first treatment, this study may be able to use your health information to help guide future care.

Lenvatinib plus immunotherapy after prior liver cancer treatment

This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.

Telephone support for advanced GI cancer and caregivers

This study offers telephone-based support for people with advanced gastrointestinal cancer who are experiencing fatigue, and for their family caregivers. It aims to help both you and your caregiver manage the challenges of cancer care together.

Iron nanoparticle injection for advanced solid tumors

This trial tests a new treatment for advanced solid tumors that uses tiny iron particles guided by carbon nanoparticles, injected directly into the tumor. It may be an option if standard treatments have stopped working or aren't available, and you have a tumor that can be safely injected.

Cabozantinib plus enfortumab for advanced bladder cancer after immunotherapy

This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.

KN510713 with mFOLFIRINOX for advanced pancreatic cancer

This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.

Testing a new cancer drug for advanced solid tumors

This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.

Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors